Clopidogrel but Not Prasugrel Significantly Inhibits the CYP2C8-Mediated Metabolism of Montelukast in Humans

Clinical Pharmacology and Therapeutics

Volumn 104, Issue 3, 2018, Pages 495-504

  Itkonen, Matti K ^a   Tornio, Aleksi ^a   Filppula, Anne M ^a,b   Neuvonen, Mikko ^a   Neuvonen, Pertti J ^a   Niemi, Mikko ^a   Backman, Janne T ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CLOPIDOGREL; CYTOCHROME P450 2C8; MONTELUKAST; PLACEBO; PRASUGREL; ACETIC ACID; ANTITHROMBOCYTIC AGENT; CYP2C8 PROTEIN, HUMAN; CYTOCHROME P450 2C8 INHIBITOR; LEUKOTRIENE RECEPTOR BLOCKING AGENT; QUINOLINE DERIVATIVE;

ADULT; AREA UNDER THE CURVE; ARTICLE; AUC (0-7 H); CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; ENZYME INHIBITION; FEMALE; GENOTYPE; HUMAN; HUMAN EXPERIMENT; MALE; MAXIMUM CONCENTRATION; NORMAL HUMAN; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TIME TO MAXIMUM PLASMA CONCENTRATION; BIOLOGICAL MODEL; BLOOD; COMPARATIVE STUDY; COMPUTER SIMULATION; DRUG INACTIVATION; DRUG INTERACTION; ENZYME SPECIFICITY; GENETICS; METABOLISM; OXIDATION REDUCTION REACTION; PHARMACOGENETIC VARIANT; PHARMACOGENETICS; RISK ASSESSMENT; YOUNG ADULT;

ACETATES; ADULT; CLOPIDOGREL; COMPUTER SIMULATION; CROSS-OVER STUDIES; CYTOCHROME P-450 CYP2C8; CYTOCHROME P-450 CYP2C8 INHIBITORS; DRUG INTERACTIONS; FEMALE; HEALTHY VOLUNTEERS; HUMANS; INACTIVATION, METABOLIC; LEUKOTRIENE ANTAGONISTS; MALE; MODELS, BIOLOGICAL; OXIDATION-REDUCTION; PHARMACOGENETICS; PHARMACOGENOMIC VARIANTS; PLATELET AGGREGATION INHIBITORS; PRASUGREL HYDROCHLORIDE; QUINOLINES; RISK ASSESSMENT; SUBSTRATE SPECIFICITY; YOUNG ADULT;

EID: 85038968903     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/cpt.947     Document Type: Article

References (31)

1. Altman, L.C. et al. A placebo-controlled, dose-ranging study of montelukast, a cysteinyl leukotriene-receptor antagonist. Montelukast Asthma Study Group. J. Allergy Clin. Immunol. 102, 50–56 (1998).
2. Lipworth, B.J. Leukotriene-receptor antagonists. Lancet 353, 57–62 (1999).
3. Reiss, T.F., Chervinsky, P., Dockhorn, R.J., Shingo, S., Seidenberg, B. & Edwards, T.B. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Montelukast Clinical Research Study Group. Arch. Intern. Med. 158, 1213–1220 (1998).
4. Cheng, H. et al. Pharmacokinetics, bioavailability, and safety of montelukast sodium (MK-0476) in healthy males and females. Pharm. Res. 13, 445–448 (1996).
5. Balani, S.K. et al. Metabolic profiles of montelukast sodium (Singulair), a potent cysteinyl leukotriene1 receptor antagonist, in human plasma and bile. Drug Metab. Dispos. 25, 1282–1287 (1997).
6. US Food and Drug Administration. Center for Drug Evaluation and Research. Pharmacology review(s) for Singulair (1998).
7. Karonen, T., Neuvonen, P.J. & Backman, J.T. CYP2C8 but not CYP3A4 is important in the pharmacokinetics of montelukast. Br. J. Clin. Pharmacol. 73, 257–267 (2012).
8. Karonen, T., Filppula, A., Laitila, J., Niemi, M., Neuvonen, P.J. & Backman, J.T. Gemfibrozil markedly increases the plasma concentrations of montelukast: a previously unrecognized role for CYP2C8 in the metabolism of montelukast. Clin. Pharmacol. Ther. 88, 223–230 (2010).
9. Filppula, A.M., Laitila, J., Neuvonen, P.J. & Backman, J.T. Reevaluation of the microsomal metabolism of montelukast: major contribution by CYP2C8 at clinically relevant concentrations. Drug Metab. Dispos. 39, 904–911 (2011).
10. Backman, J.T., Filppula, A.M., Niemi, M. & Neuvonen, P.J. Role of cytochrome P450 2C8 in drug metabolism and interactions. Pharmacol. Rev. 68, 168–241 (2016).
11. VandenBrink, B.M., Foti, R.S., Rock, D.A., Wienkers, L.C. & Wahlstrom, J.L. Evaluation of CYP2C8 inhibition in vitro: utility of montelukast as a selective CYP2C8 probe substrate. Drug Metab. Dispos. 39, 1546–1554 (2011).
12. Cardoso Jde, O., Oliveira, R.V., Lu, J.B. & Desta, Z. In vitro metabolism of montelukast by cytochrome P450s and UDP-glucuronosyltransferases. Drug Metab. Dispos. 43, 1905–1916 (2015).
13. Varma, M.V. et al. Transporter-mediated hepatic uptake plays an important role in the pharmacokinetics and drug-drug interactions of montelukast. Clin. Pharmacol. Ther. 101, 406–415 (2017).
14. Hirvensalo, P. et al. Comprehensive pharmacogenomic study reveals an important role of UGT1A3 in montelukast pharmacokinetics. Clin. Pharmacol. Ther. doi: 10.1002/cpt.891. (2017) [Epub ahead of print].
15. Tornio, A. et al. Glucuronidation converts clopidogrel to a strong time-dependent inhibitor of CYP2C8: a phase II metabolite as a perpetrator of drug-drug interactions. Clin. Pharmacol. Ther. 96, 498–507 (2014).
16. Itkonen, M.K., Tornio, A., Neuvonen, M., Neuvonen, P.J., Niemi, M. & Backman, J.T. Clopidogrel markedly increases plasma concentrations of CYP2C8 substrate pioglitazone. Drug Metab. Dispos. 44, 1364–1371 (2016).
17. Kim, S.J. et al. Clarification of the mechanism of clopidogrel-mediated drug-drug interaction in a clinical cassette small-dose study and its prediction based on in vitro information. Drug Metab. Dispos. 44, 1622–1632 (2016).
18. Itkonen, M.K., Tornio, A., Neuvonen, M., Neuvonen, P.J., Niemi, M. & Backman, J.T. Clopidogrel has no clinically meaningful effect on the pharmacokinetics of the organic anion transporting polypeptide 1B1 and cytochrome P450 3A4 substrate simvastatin. Drug Metab. Dispos. 43, 1655–1660 (2015).
19. Neuvonen, P.J., Niemi, M. & Backman, J.T. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin. Pharmacol. Ther. 80, 565–581 (2006).
20. Wiviott, S.D. et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 357, 2001–2015 (2007).
21. Wallentin, L. et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 361, 1045–1057 (2009).
22. Farid, N.A. et al. The disposition of prasugrel, a novel thienopyridine, in humans. Drug Metab. Dispos. 35, 1096–1104 (2007).
23. Jaakkola, T., Backman, J.T., Neuvonen, M., Niemi, M. & Neuvonen, P.J. Montelukast and zafirlukast do not affect the pharmacokinetics of the CYP2C8 substrate pioglitazone. Eur. J. Clin. Pharmacol. 62, 503–509 (2006).
24. Chiba, M., Xu, X., Nishime, J.A., Balani, S.K. & Lin, J.H. Hepatic microsomal metabolism of montelukast, a potent leukotriene D4 receptor antagonist, in humans. Drug Metab. Dispos. 25, 1022–1031 (1997).
25. Hegazy, S.K., Mabrouk, M.M., Elsisi, A.E. & Mansour, N.O. Effect of clarithromycin and fluconazole on the pharmacokinetics of montelukast in human volunteers. Eur. J. Clin. Pharmacol. 68, 1275–1280 (2012).
26. Jaakkola, T., Backman, J.T., Neuvonen, M. & Neuvonen, P.J. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics of pioglitazone. Clin. Pharmacol. Ther. 77, 404–414 (2005).
27. Aquilante, C.L. et al. Impact of the CYP2C8 *3 polymorphism on the drug-drug interaction between gemfibrozil and pioglitazone. Br. J. Clin. Pharmacol. 75, 217–226 (2013).
28. Deng, L.J., Wang, F. & Li, H.D. Effect of gemfibrozil on the pharmacokinetics of pioglitazone. Eur. J. Clin. Pharmacol. 61, 831–836 (2005).
29. Tornio, A., Neuvonen, P.J., Niemi, M. & Backman, J.T. Role of gemfibrozil as an inhibitor of CYP2C8 and membrane transporters. Expert Opin. Drug Metab. Toxicol. 13, 83–95 (2017).
30. Delavenne, X., Basset, T., Zufferey, P., Malouk, N., Laporte, S. & Mismetti, P. Ultra-performance LC MS/MS method for quantification of clopidogrel active metabolite. J. Sep. Sci. 33, 1968–1972 (2010).
31. Holmberg, M.T. et al. Effect of grapefruit juice on the bioactivation of prasugrel. Br. J. Clin. Pharmacol. 80, 139–145 (2015).